Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients

John P. Diaz, Nadeem R. Abu-Rustum, Yukio Sonoda, Robert J. Downey, Bernard J. Park, Raja M. Flores, Kaity Chang, Mario M. Leitao, Richard R. Barakat, Dennis S. Chi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objectives: To assess the utility of thoracoscopy in defining the extent of intrathoracic disease and survival outcomes in patients with moderate to large pleural effusions at the time of diagnosis of advanced ovarian carcinoma. Methods: We reviewed the records of all patients with untreated advanced ovarian carcinoma and moderate to large pleural effusions who underwent video-assisted thoracoscopic surgery (VATS) our institution between 6/01 and 10/08. Demographic, clinicopathologic and outcome data were collected for all patients with a final diagnosis of ovarian carcinoma. Results: Forty-two patients met eligibility criteria, with a median age of 58 years; median CA-125 level of 1747 U/mL; and medium serum albumin of 3.9 g/dl. VATS was performed for right-sided effusions in 30 patients (71%). Macroscopic pleural disease was found in 29 patients (69%). Of the 11 patients with negative cytology, macroscopic pleural disease was found in 4 (36%). Intrathoracic cytoreductive surgery was performed in 6 (33%) of the 18 patients with intrathoracic disease > 1 cm. After VATS, 29/42 (69%) patients underwent attempted primary abdominal surgical debulking. Thirteen patients (31%) received neoadjuvant chemotherapy. Twelve (92%) of these patients underwent interval cytoreductive surgery. Patients who were directed after VATS to neoadjuvant chemotherapy instead of primary surgical cytoreduction had a 2-year PFS rate of 22% compared to 42% for the primary cytoreductive group (P = 0.36). Conclusions: Overall, management was altered based on VATS findings in 43% of cases. Further investigation is needed to define the prognostic significance of VATS evaluation of the burden of pleural disease.

Original languageEnglish
Pages (from-to)483-488
Number of pages6
JournalGynecologic Oncology
Volume116
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

Video-Assisted Thoracic Surgery
Pleural Effusion
Carcinoma
Pleural Diseases
Drug Therapy
Thoracoscopy
Serum Albumin
Cell Biology

Keywords

  • Advanced ovarian carcinoma
  • Pleural disease
  • Thracoscopy
  • VATS

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. / Diaz, John P.; Abu-Rustum, Nadeem R.; Sonoda, Yukio; Downey, Robert J.; Park, Bernard J.; Flores, Raja M.; Chang, Kaity; Leitao, Mario M.; Barakat, Richard R.; Chi, Dennis S.

In: Gynecologic Oncology, Vol. 116, No. 3, 01.03.2010, p. 483-488.

Research output: Contribution to journalArticle

Diaz, John P. ; Abu-Rustum, Nadeem R. ; Sonoda, Yukio ; Downey, Robert J. ; Park, Bernard J. ; Flores, Raja M. ; Chang, Kaity ; Leitao, Mario M. ; Barakat, Richard R. ; Chi, Dennis S. / Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. In: Gynecologic Oncology. 2010 ; Vol. 116, No. 3. pp. 483-488.
@article{e103605acd864812b4eb0f02811e34aa,
title = "Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients",
abstract = "Objectives: To assess the utility of thoracoscopy in defining the extent of intrathoracic disease and survival outcomes in patients with moderate to large pleural effusions at the time of diagnosis of advanced ovarian carcinoma. Methods: We reviewed the records of all patients with untreated advanced ovarian carcinoma and moderate to large pleural effusions who underwent video-assisted thoracoscopic surgery (VATS) our institution between 6/01 and 10/08. Demographic, clinicopathologic and outcome data were collected for all patients with a final diagnosis of ovarian carcinoma. Results: Forty-two patients met eligibility criteria, with a median age of 58 years; median CA-125 level of 1747 U/mL; and medium serum albumin of 3.9 g/dl. VATS was performed for right-sided effusions in 30 patients (71{\%}). Macroscopic pleural disease was found in 29 patients (69{\%}). Of the 11 patients with negative cytology, macroscopic pleural disease was found in 4 (36{\%}). Intrathoracic cytoreductive surgery was performed in 6 (33{\%}) of the 18 patients with intrathoracic disease > 1 cm. After VATS, 29/42 (69{\%}) patients underwent attempted primary abdominal surgical debulking. Thirteen patients (31{\%}) received neoadjuvant chemotherapy. Twelve (92{\%}) of these patients underwent interval cytoreductive surgery. Patients who were directed after VATS to neoadjuvant chemotherapy instead of primary surgical cytoreduction had a 2-year PFS rate of 22{\%} compared to 42{\%} for the primary cytoreductive group (P = 0.36). Conclusions: Overall, management was altered based on VATS findings in 43{\%} of cases. Further investigation is needed to define the prognostic significance of VATS evaluation of the burden of pleural disease.",
keywords = "Advanced ovarian carcinoma, Pleural disease, Thracoscopy, VATS",
author = "Diaz, {John P.} and Abu-Rustum, {Nadeem R.} and Yukio Sonoda and Downey, {Robert J.} and Park, {Bernard J.} and Flores, {Raja M.} and Kaity Chang and Leitao, {Mario M.} and Barakat, {Richard R.} and Chi, {Dennis S.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.ygyno.2009.09.047",
language = "English",
volume = "116",
pages = "483--488",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients

AU - Diaz, John P.

AU - Abu-Rustum, Nadeem R.

AU - Sonoda, Yukio

AU - Downey, Robert J.

AU - Park, Bernard J.

AU - Flores, Raja M.

AU - Chang, Kaity

AU - Leitao, Mario M.

AU - Barakat, Richard R.

AU - Chi, Dennis S.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Objectives: To assess the utility of thoracoscopy in defining the extent of intrathoracic disease and survival outcomes in patients with moderate to large pleural effusions at the time of diagnosis of advanced ovarian carcinoma. Methods: We reviewed the records of all patients with untreated advanced ovarian carcinoma and moderate to large pleural effusions who underwent video-assisted thoracoscopic surgery (VATS) our institution between 6/01 and 10/08. Demographic, clinicopathologic and outcome data were collected for all patients with a final diagnosis of ovarian carcinoma. Results: Forty-two patients met eligibility criteria, with a median age of 58 years; median CA-125 level of 1747 U/mL; and medium serum albumin of 3.9 g/dl. VATS was performed for right-sided effusions in 30 patients (71%). Macroscopic pleural disease was found in 29 patients (69%). Of the 11 patients with negative cytology, macroscopic pleural disease was found in 4 (36%). Intrathoracic cytoreductive surgery was performed in 6 (33%) of the 18 patients with intrathoracic disease > 1 cm. After VATS, 29/42 (69%) patients underwent attempted primary abdominal surgical debulking. Thirteen patients (31%) received neoadjuvant chemotherapy. Twelve (92%) of these patients underwent interval cytoreductive surgery. Patients who were directed after VATS to neoadjuvant chemotherapy instead of primary surgical cytoreduction had a 2-year PFS rate of 22% compared to 42% for the primary cytoreductive group (P = 0.36). Conclusions: Overall, management was altered based on VATS findings in 43% of cases. Further investigation is needed to define the prognostic significance of VATS evaluation of the burden of pleural disease.

AB - Objectives: To assess the utility of thoracoscopy in defining the extent of intrathoracic disease and survival outcomes in patients with moderate to large pleural effusions at the time of diagnosis of advanced ovarian carcinoma. Methods: We reviewed the records of all patients with untreated advanced ovarian carcinoma and moderate to large pleural effusions who underwent video-assisted thoracoscopic surgery (VATS) our institution between 6/01 and 10/08. Demographic, clinicopathologic and outcome data were collected for all patients with a final diagnosis of ovarian carcinoma. Results: Forty-two patients met eligibility criteria, with a median age of 58 years; median CA-125 level of 1747 U/mL; and medium serum albumin of 3.9 g/dl. VATS was performed for right-sided effusions in 30 patients (71%). Macroscopic pleural disease was found in 29 patients (69%). Of the 11 patients with negative cytology, macroscopic pleural disease was found in 4 (36%). Intrathoracic cytoreductive surgery was performed in 6 (33%) of the 18 patients with intrathoracic disease > 1 cm. After VATS, 29/42 (69%) patients underwent attempted primary abdominal surgical debulking. Thirteen patients (31%) received neoadjuvant chemotherapy. Twelve (92%) of these patients underwent interval cytoreductive surgery. Patients who were directed after VATS to neoadjuvant chemotherapy instead of primary surgical cytoreduction had a 2-year PFS rate of 22% compared to 42% for the primary cytoreductive group (P = 0.36). Conclusions: Overall, management was altered based on VATS findings in 43% of cases. Further investigation is needed to define the prognostic significance of VATS evaluation of the burden of pleural disease.

KW - Advanced ovarian carcinoma

KW - Pleural disease

KW - Thracoscopy

KW - VATS

UR - http://www.scopus.com/inward/record.url?scp=75749083965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749083965&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.09.047

DO - 10.1016/j.ygyno.2009.09.047

M3 - Article

C2 - 19945741

AN - SCOPUS:75749083965

VL - 116

SP - 483

EP - 488

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -